comprehensive -WSS

comprehensive

author：focus 2025-09-30 16:27:58 - browse：15

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Why Novartis is changing the name of its research labs

entertainment

explore

WSS

Snackable artificial intelligence, expert AI, and the pharma industry

Listen: Biogen's potential pivot, & Illumina's next chapter

'Make People Better': The CRISPR babies story you probably don't know

A new House health package & hospitals’ new site

Pope Francis asks Church to identify 21st

Pope Francis asks Church to identify 21st

focus

comprehensive

Wikipedia

Wildfire smoke exposes gaps in outdoor worker protections

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Tori Bowie and the unacceptable rates of Black maternal death

Covid hospitalizations on the rise, Humana says

The high cost of giving birth even with insurance

ALS advocates say criticism of new drugs misses bigger picture

Cancer drug shortages should be causing more outrage

House transparency, PBM reform bill gains bipartisan support

Medical leaders decry Supreme Court decision on affirmative action

Ethical issues complicate the benefits of medical crowdfunding

knowledge

EU moves toward latest gene techniques in food production to counter climate change, shortages

Pentagon will tighten controls on classified information after Discord leak

Myanmar's Supreme Court hears arguments in 2 appeals by ousted leader Aung San Suu Kyi

The (many) problems with a new study criticizing cancer screening

China dismisses criticism of top diplomat's comments appearing to push for race

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

entertainment

entertainment

explore

leisure time